Integrated Piotroski F Score

INBP -  USA Stock  

USD 1.08  0.02  1.82%

This module uses fundamental data of Integrated Biopharma to approximate its Piotroski F score. Integrated Biopharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Integrated Biopharma. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Integrated Biopharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please see Integrated Biopharma Altman Z Score, Integrated Biopharma Correlation, Integrated Biopharma Valuation, as well as analyze Integrated Biopharma Alpha and Beta and Integrated Biopharma Hype Analysis.

Integrated Piotroski F Score 

 
Refresh
Integrated Biopharma Total Debt is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Total Debt of 6 Million. As of 28th of October 2021, Debt Current is likely to grow to about 6 M, while Issuance Repayment of Debt Securities is likely to drop (3.1 M). Integrated Biopharma Free Cash Flow per Share is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Free Cash Flow per Share of 0.09. As of 28th of October 2021, Gross Margin is likely to grow to 0.15, while EBITDA Margin is likely to drop 0.11.
At this time, it appears that Integrated Biopharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On Assets
Positive
2
Change in Return on Assets
Decreased
3
Cash Flow Return on Assets
Positive
4
Current Quality of Earnings (accrual)
Decreasing
5
Asset Turnover Growth
Decrease
6
Current Ratio Change
Decrease
7
Long Term Debt Over Assets Change
Higher Leverage
8
Change In Outstending Shares
Increase
9
Change in Gross Margin
Increase

Integrated Biopharma Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Integrated Biopharma is to make sure Integrated is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Integrated Biopharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Integrated Biopharma's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares29.9 M29.7 M
Slightly Up
Increasing
Slightly volatile
Weighted Average Shares Diluted33.8 M32.1 M
Sufficiently Up
Increasing
Slightly volatile
Net Cash Flow from Operations3.3 MM
Significantly Up
Increasing
Slightly volatile
Total Assets23.6 M25.4 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities13.7 M11.1 M
Fairly Up
Decreasing
Slightly volatile
Current Assets17.3 M18 M
Sufficiently Down
Increasing
Slightly volatile
Current Liabilities10 M9.2 M
Significantly Up
Decreasing
Stable
Total Debt8.5 MM
Significantly Up
Decreasing
Slightly volatile
Return on Average Assets0.260.316
Significantly Down
Increasing
Slightly volatile
Gross Margin0.150.149
Slightly Up
Increasing
Slightly volatile
Asset Turnover2.492.506
Slightly Down
Decreasing
Slightly volatile

Integrated Biopharma F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Integrated Biopharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Integrated Biopharma in a much-optimized way.

About Integrated Biopharma Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

0.52Share
Integrated Biopharma Book Value per Share is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Book Value per Share of 0.48

Integrated Biopharma Current Valuation Drivers

We derive many important indicators used in calculating different scores of Integrated Biopharma from analyzing Integrated Biopharma's financial statements. These drivers represent accounts that assess Integrated Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Integrated Biopharma's important valuation drivers and their relationship over time.
201620172018201920202021 (projected)
Average Assets14.61 M14.55 M21.08 M20.8 M25.37 M23.96 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings Before Interest Taxes and Depreciation Amortization USD3.16 M2.28 M3.45 M4.26 M8.33 M8.99 M
Earnings before Tax1.86 M1 M2.04 M3.09 M7.25 M7.82 M
Average Equity(7.2 M)(5.96 M)985.75 K3.91 M9.91 M10.69 M
Enterprise Value18.4 M17.26 M16.52 M21.91 M40.83 M34.28 M
Free Cash Flow70 K927 K(86 K)1.13 M2.75 M2.97 M
Invested Capital19.17 M12.72 M19.86 M20.58 M21.99 M21.9 M
Invested Capital Average18.29 M16.28 M17.58 M18.53 M20.21 M20.89 M
Market Capitalization4.01 M3.17 M6.8 M13.3 M32.75 M35.33 M
Tangible Asset Value15.2 M14.57 M19.79 M22.94 M25.44 M23.54 M
Working Capital1.4 M(3.92 M)1.73 M3.36 M8.76 M9.45 M

About Integrated Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Integrated Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.

Integrated Biopharma Investors Sentiment

The influence of Integrated Biopharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Integrated. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - INBP

Integrated Biopharma Investor Sentiment

Most of Macroaxis users are currently bullish on Integrated Biopharma. What is your judgment towards investing in Integrated Biopharma? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Integrated Biopharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Integrated Biopharma Altman Z Score, Integrated Biopharma Correlation, Integrated Biopharma Valuation, as well as analyze Integrated Biopharma Alpha and Beta and Integrated Biopharma Hype Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.